Evidence map›Paper›PMID 41604543›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Enantioselective Reductive Alkenylation of α-CF

Peng Liu, Kuiliang Li, Yan He, Chen-Hui Jiang, Ruo-Xing Jin, Duo-Duo Hu, Wei-Cheng Zhao, Xuan Nie, Shang-Zheng Sun, Xi-Sheng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peng LiuDepartment of Pharmacy, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Kuiliang LiSchool of Chemical and Blasting Engineering, Anhui University of Science and Technology, Huainan, China.
Yan HeDepartment of Chemistry, University of Science and Technology of China, Hefei, China.
Chen-Hui JiangDepartment of Chemistry, University of Science and Technology of China, Hefei, China.
Ruo-Xing JinDepartment of Chemistry, University of Science and Technology of China, Hefei, China.
Duo-Duo HuSchool of Chemical and Blasting Engineering, Anhui University of Science and Technology, Huainan, China.
Wei-Cheng ZhaoDepartment of Chemistry, University of Science and Technology of China, Hefei, China.
Xuan NieDepartment of Pharmacy, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Shang-Zheng SunDepartment of Chemistry, University of Science and Technology of China, Hefei, China.
Xi-Sheng WangDepartment of Pharmacy, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.ORCID https://orcid.org/0000-0003-2398-5669

Funding

National Basic Research Program of China (973 Program)National Natural Science Foundation of China 52203196
6 · The paper itself

Abstract

The incorporation of fluoroalkyl groups into drug candidates has garnered increasing attention in the pharmaceutical industry due to their ability to modulate lipophilicity, permeability, metabolic stability, and binding affinity. Despite significant advances realized, the means to introducing fluoroalkyl groups such as ─CF

Indexed as

CF2H synthonsenantioselectivenickel catalysisreductive couplingα‐CF2H amines

Identifiers

PMID41604543
PMCPMC13042639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.